Gland Pharma share price
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Gland Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2020 · Issue price ₹1,500
Last close ₹3,049.00up ₹88.70 (3.00%)BSE ₹3,047.30
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,960.30.
28 Oct: open ₹2,950.00, high ₹3,061.50, low ₹2,924.00
52-week range of traded prices to 28 Oct 2026
₹1,573.60Low, 16 Mar 2026₹3,171.00High, 7 Oct 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹50,312 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.66%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,82,54245.7% delivered
About Gland Pharma
Gland Pharma Limited makes sterile injectable medicines.12 It works mainly business to business, supplying other pharmaceutical companies, and also develops and manufactures medicines for drug makers under contract, as a contract development and manufacturing organisation (CDMO).2 Its plants are in Hyderabad and Visakhapatnam in India, and in France and Belgium through its subsidiary Cenexi.3
Its medicines come as vials, pre-filled syringes, ampoules, infusion bags, eye drops, pens and cartridges, and cover areas including cancer, eye care, nervous system disorders, pain, infections, heart disease and hormones.42 Its products include the blood thinners enoxaparin and heparin, the antibiotic daptomycin and the antifungals caspofungin and micafungin.5 In India it also sells directly to hospitals, nursing homes and government facilities.45
It was established in Hyderabad in 1978 and began as a contract manufacturer of small-volume liquid injectables.6 It listed on the NSE and BSE in 2020.7 It acquired Cenexi, which gave it manufacturing and development sites in Europe.8 Srinivas Sadu is Executive Chairman; chief executive Shyamakant Giri resigned with effect from 30 Apr 2026.910
The company is a subsidiary of Fosun Pharma Industrial Pte. Ltd., a Singapore company that is its promoter.1011
Gland Pharma key points
Results
- In the quarter to Jun 2026, consolidated revenue rose 20% to ₹18,003 million, reported EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹4,930 million, a 27% margin against 24% a year earlier, and profit after tax rose 47% to ₹3,170 million.1213
- In the year to Mar 2026, consolidated revenue rose 14.5% to ₹64,307 million from ₹56,165 million, EBITDA rose 28% to ₹16,295 million from ₹12,689 million and profit after tax rose 47% to ₹10,273 million.1415
- In the quarter to Jun 2026, contract development and manufacturing (CDMO) brought in ₹8,915 million, up 20%, and sales to other drug companies (B2B) ₹9,088 million, up 19%; each was 50% of revenue.16
- Cenexi, its European subsidiary, had revenue of €182 million in the year to Mar 2026, and €48 million with EBITDA of €2 million in the quarter to Jun 2026.1517
Where revenue comes from
Plants and capacity
- It has 4 plants making finished medicines in India and Cenexi has 4 in Europe, plus 3 plants making active pharmaceutical ingredients (APIs).2122
- The company states an annual capacity of 1.7 billion units across its facilities.23
- It has expanded its cartridge fill-finish capacity for GLP-1 medicines (a class of diabetes and weight-loss drugs) from 40 million to 140 million units a year.2425
Customers and partners
- The company says it has access to 13 of the top 15 US generic injectable companies and more than 200 partnerships with pharmaceutical companies worldwide.2620
- On its earnings call of 10 Aug 2026, the company said it had agreed with a global pharmaceutical company to make 55 injectable products (stock-keeping units) at 3 sites, with revenue potential of about $90 million to $100 million once launched, from 2029.2728
- Its annual report for the year to Mar 2026 says it has signed 8 contract manufacturing deals for GLP-1 programmes; on its call of 10 Aug 2026 it said it signed a new one that quarter, for semaglutide and tirzepatide in the US and Europe.293031
Research and development
- By Jun 2026 it and its partners had filed 389 applications to sell generic medicines in the US (ANDAs), with 342 approved and 47 pending; 3 were filed and 7 approved that quarter.32
- It spent ₹772 million on research and development in the quarter to Jun 2026, 4% of consolidated revenue, and ₹2,230 million in the year to Mar 2026.3220
- In its presentation of 10 Aug 2026, the company said 15 products were in development with partners, 7 by the US 505(b)(2) route (for changed versions of approved drugs) and 8 as ANDAs, with sales from the year to Mar 2028.33
Expansion and capital spending
What the company expects
- On its earnings call of 10 Aug 2026, the company said it is trying to maintain 15% constant-currency revenue growth (excluding exchange-rate changes) in the year to Mar 2027, and as of now looks at around 20% over the next 4 years.3738
- On its earnings call of 10 Aug 2026, the company said it is working towards a consolidated EBITDA margin of 30% in the near term, from an adjusted 28% (before a non-cash share-option expense), and hopes to reach 35% in 3 to 4 years.3940
Recent events
- A US FDA inspection of the Dundigal plant from 12 to 23 Oct 2026 ended with 4 Form 483 observations (issues an inspector lists for correction), which the company called procedural and not related to data integrity.4142
- The board approved investing $21 million in Gland Pharma USA to take 60% of Novelstar Pharma, a US company; Fosun Pharma USA, a sister company of its promoter, is to own the other 40%.4344
- The company won US FDA approval for its sugammadex injection, which reverses muscle relaxants used in surgery, and launched it through its marketing partner; it cites market data putting US sales of the product at about $1.6 billion in the year to Apr 2026.4546
- A customs order confirmed an integrated goods and services tax (IGST) demand of ₹3,52,93,678 for the years to Mar 2021 and Mar 2022, with interest and an equal penalty; on 16 Jul 2026 it said it was appealing, and its documents give no later status.4748
Last updated
All 48 sources, each with its page
- 1. Annual report, 31 Jul 2026, page 130
- 2. Annual report, 31 Jul 2026, page 24
- 3. Annual report, 31 Jul 2026, page 46
- 4. Annual report, 31 Jul 2026, page 34
- 5. Annual report, 31 Jul 2026, page 24
- 6. Exchange filing, 29 Jul 2026, page 2
- 7. Annual report, 31 Jul 2026, page 78
- 8. Annual report, 31 Jul 2026, page 27
- 9. Earnings call, 10 Aug 2026, page 3
- 10. Annual report, 31 Jul 2026, page 92
- 11. Exchange filing, 1 Oct 2026, page 5
- 12. Earnings call, 10 Aug 2026, page 7
- 13. Earnings call, 10 Aug 2026, page 8
- 14. Annual report, 31 Jul 2026, page 29
- 15. Annual report, 31 Jul 2026, page 30
- 16. Earnings call, 10 Aug 2026, page 4
- 17. Earnings call, 10 Aug 2026, page 6
- 18. Earnings call, 10 Aug 2026, page 4
- 19. Earnings call, 10 Aug 2026, page 5
- 20. Annual report, 31 Jul 2026, page 24
- 21. Annual report, 31 Jul 2026, page 34
- 22. Annual report, 31 Jul 2026, page 46
- 23. Annual report, 31 Jul 2026, page 44
- 24. Annual report, 31 Jul 2026, page 77
- 25. Annual report, 31 Jul 2026, page 30
- 26. Annual report, 31 Jul 2026, page 37
- 27. Earnings call, 10 Aug 2026, page 5
- 28. Investor presentation, 10 Aug 2026, page 11
- 29. Annual report, 31 Jul 2026, page 38
- 30. Earnings call, 10 Aug 2026, page 5
- 31. Earnings call, 10 Aug 2026, page 12
- 32. Investor presentation, 10 Aug 2026, page 11
- 33. Investor presentation, 10 Aug 2026, page 11
- 34. Earnings call, 10 Aug 2026, page 8
- 35. Annual report, 31 Jul 2026, page 30
- 36. Earnings call, 10 Aug 2026, page 10
- 37. Earnings call, 10 Aug 2026, page 12
- 38. Earnings call, 10 Aug 2026, page 11
- 39. Earnings call, 10 Aug 2026, page 12
- 40. Earnings call, 10 Aug 2026, page 8
- 41. Exchange filing, 23 Oct 2026, page 1
- 42. Exchange filing, 23 Oct 2026, page 1
- 43. Exchange filing, 1 Oct 2026, page 1
- 44. Exchange filing, 1 Oct 2026, page 5
- 45. Exchange filing, 29 Jul 2026, page 1
- 46. Exchange filing, 29 Jul 2026, page 2
- 47. Exchange filing, 16 Jul 2026, page 1
- 48. Exchange filing, 16 Jul 2026, page 2
Results
Consolidated; ₹ crore.Gland Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +17.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +46.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,800 Crup 3.30%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹317 Crdown 13.56%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 17.6%
Revenue by quarter
Peak revenue ₹1,800 Cr, quarter to Jun 2026; lowest ₹1,384 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Net profit | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| Net margin | 11.6% | 14.8% | 13.1% | 14.3% | 12.4% | 15.4% | 21.0% | 17.6% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹6,431 Crup 14.50%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,027 Crup 47.07%
- Net margin
- 16.0%
Revenue by year
Peak revenue ₹6,431 Cr, year to Mar 2026; lowest ₹3,463 Cr, year to Mar 2021
Net profit by year, a loss in red
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 3,463 | 4,401 | 3,625 | 5,665 | 5,617 | 6,431 |
| Net profit | 997 | 1,212 | 781 | 772 | 699 | 1,027 |
| Net margin | 28.8% | 27.5% | 21.5% | 13.6% | 12.4% | 16.0% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Gland Pharma PE ratio and valuation
Price to earnings
At or below today's level on 83% of 1,239 trading days over the last 5 years.
LowestHighest
Its median38.39Industry median27.98
Price to book
At or below today's level on 80% of 1,239 trading days over the last 5 years.
LowestHighest
Its median3.48Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 57% of 1,239 trading days over the last 5 years.
LowestHighest
Its median0.00%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +7.7% | +47.1% | −27.6% | 1.2% |
| 3 years | +11.3% | +9.5% | +0.6% | 1.1% |
| 5 years | −6.6% | +0.5% | −7.7% | 0.7% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
169 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 61 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 169 funds holding Gland Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 12
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 14
- AddedAdded. Funds that held more shares than at the end of the month before.
- 40
- CutCut. Funds that held fewer shares than at the end of the month before.
- 53
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 50
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 5
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 60,67,814 | 1.73% | ₹1,759.3 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 36,65,817 | 1.60% | ₹1,062.9 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 31,86,587 | 2.28% | ₹923.9 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 28,00,000 | 1.62% | ₹811.8 Cr |
| Nippon India Small Cap FundNippon India Mutual Fund | 18,32,424 | 0.66% | ₹531.3 Cr |
 Mirae Asset Large & Midcap FundMirae Asset Mutual Fund | 16,94,152 | 1.15% | ₹491.2 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 14,00,000 | 1.42% | ₹405.9 Cr |
 DSP Small Cap FundDSP Mutual Fund | 13,15,806 | 1.78% | ₹381.5 Cr |
 Axis Small Cap FundAxis Mutual Fund | 12,87,862 | 1.22% | ₹373.4 Cr |
 ICICI Prudential India Opportunities FundICICI Prudential Mutual Fund | 12,63,529 | 1.00% | ₹366.3 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Gland Pharma insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Employees0 purchases, 4 salesNo purchase₹0.28 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹0.28 Cr
- Others0 purchases, 8 salesNo purchase₹1.45 CrNet−₹1.45 Cr17 pledge filings of unclear kind
- Promoters and promoter group: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Gland Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Gland Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Glenmark PharmaceuticalsGLENMARK | 64,912 | 36.10 | 6.17 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 Alkem LaboratoriesALKEM | 60,619 | 28.10 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.05% |
 BioconBIOCON | 57,153 | 115.39 | 1.68 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,833 | 34.58 | 11.69 | +6.3% | +11.2% | 35.9% | 39.6% | 2.50% |
 IPCA LaboratoriesIPCALAB | 48,978 | 37.39 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 43,233 | 38.10 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Gland Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹20.00 a share, years to Mar 2024 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 11 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹20.00 |
| 14 Aug 2025 | Final | ₹18.00 |
| 16 Aug 2024 | Final | ₹20.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Gland Pharma announcements
Oct 2026
21 Oct · Analysts
21 Oct · Board meeting
6 Oct · Meeting
1 Oct · Management
1 Oct · Board meeting
Gland Pharma share price by year
Each calendar year to 2025.Gland Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,722.00 | −3.2% | 2,102.10 | 1,392.80 |
| 2024 | 1,779.35 | −7.5% | 2,141.60 | 1,605.85 |
| 2023 | 1,924.50 | +22.1% | 1,947.20 | 893.55 |
| 2022 | 1,576.55 | −59.2% | 3,981.05 | 1,573.35 |
| 2021 | 3,864.55 | +65.2% | 4,316.25 | 2,078.10 |
| 2020 | 2,339.75 | – | 2,408.35 | 1,819.55 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 20 Nov 2020.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 2,858.90 | 3,000.00 | 2,858.90 | 2,960.30 | 2,965.99 | 3,97,406 | 53.9% |
| 26 Oct 2026 | 2,815.00 | 2,867.80 | 2,788.40 | 2,843.90 | 2,832.25 | 4,80,647 | 68.7% |
| 23 Oct 2026 | 2,848.90 | 2,924.00 | 2,769.80 | 2,826.80 | 2,814.43 | 4,23,057 | 55.6% |
| 22 Oct 2026 | 2,906.10 | 2,953.90 | 2,829.00 | 2,850.40 | 2,884.47 | 3,38,424 | 55.4% |
| 21 Oct 2026 | 3,005.10 | 3,028.30 | 2,839.60 | 2,935.00 | 2,911.47 | 12,03,469 | 60.7% |
| 19 Oct 2026 | 3,046.10 | 3,075.10 | 3,002.80 | 3,019.80 | 3,038.33 | 1,67,122 | 55.5% |
| 16 Oct 2026 | 3,096.90 | 3,096.90 | 3,004.30 | 3,043.40 | 3,028.69 | 1,65,156 | 48.0% |
| 15 Oct 2026 | 3,040.20 | 3,076.90 | 3,000.10 | 3,066.30 | 3,047.46 | 1,56,231 | 53.7% |
| 14 Oct 2026 | 3,099.00 | 3,105.00 | 3,042.00 | 3,052.30 | 3,055.18 | 1,78,927 | 56.4% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- GLAND
- BSE code
- 543245
- ISIN
- INE068V01023
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.glandpharma.com
- CIN
- L24239TG1978PLC002276
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1978
- Registered office
- Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma X Roads, D.P.Pally, Dundigal, Dundigal-Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500043, Telangana
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE MidCap